Star manager joins Bill Gates in $90M biopharma bid

Neil Woodford, one of the U.K's most prominent fund managers, has joined Bill Gates in backing a small biopharmaceutical firm, with a bumper $50 million investment, bringing combined fundraising to $90 million.

Kymab, a U.K. firm that specializes in producing monoclonal antibodies, or antibodies created from clones of a single cell in a lab, rather than from a person's own immune system, announced Wednesday it had completed a second round of fundraising.

Read MoreBill Gates: Capitalism is the wrong incentive here